VIM and lip and oral cavity carcinoma: Based on the findings of the retrospective study, we undertook another cohort of patients (n = 196) with oral leukoplakia (n = 50), OSMF (n = 32), and invasive cancers involving buccal cavity (to ascertain if vimentin can be useful in oral cancer inclusive of both sites oral tongue and buccal cavity.